ANGLE plc (“the Company”) Pharma Services Contract with Crescendo Biologics
April 13, 2023Business Services
ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has signed a …
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
April 13, 2023Business Services
Strasbourg, France, April 12, 2023, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops …
Alentis Therapeutics closes $105m Series C funding for new treatment options
April 13, 2023Sales and Marketing
Alentis Therapeutics has announced $105m in Series C funding which was led by Jeito Capital together with Novo Holdings A/S …
Biogen announces licensing of Denali’s ATV to target Amyloid Beta
April 13, 2023Research and Development
Biogen and Denali Therapeutics have announced that Biogen has exercised its option to license Denali’s Antibody Transport Vehicle: Amyloid beta …
Aspect Biosystems and Novo Nordisk partner with $75m deal to develop bioprinted tissue therapeutics
April 13, 2023Research and Development
Canadian biotech company Aspect Biosystems and Denmark-based Novo Nordisk have announced a collaboration, development and license agreement to develop bioprinted …
Kala Pharmaceuticals receives FDA Fast Track Designation for human MSC-S therapy
April 13, 2023Medical Communications
Clinical-stage biopharmaceutical company Kala Pharmaceuticals has announced that the FDA has granted it Fast Track Designation for its human mesenchymal …
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) ACCEPTED FOR USE WITHIN NHS SCOTLAND EARLIER IN THE TREATMENT PATHWAY FOR HER2-POSITIVE METASTATIC BREAST CANCER
April 12, 2023Business Services
Daiichi Sankyo UK Limited and AstraZeneca UK Limited welcome the news that the Scottish Medicines Consortium (SMC) has accepted Enhertu®▼ …
Almirall, the first to assess wellbeing in a dermatology clinical study
April 12, 2023Business Services
BARCELONA, Spain. April 12, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced the …
Liberal states begin stockpiling abortion medications following Texas court ruling
April 12, 2023Medical Communications
Various liberal US states, including California and Massachusetts, have begun stockpiling abortion medications following a Texas judge Matthew Kacsmaryk’s attempt …
Moderna announces mixed success clinical updates for mRNA pipeline
April 12, 2023Research and Development
Biotechnology company Moderna has announced clinical updates detailing the expansion and advancement of its mRNA pipeline, which includes treatments for …
ImaginAb signs new license and supply agreement with Leucid Bio for CD8 ImmunoPET technology
April 12, 2023Sales and Marketing
Biotechnology company ImaginAb has announced that it has signed a new non-exclusive License and Supply Agreement (LSA) with Leucid Bio. …
Cognizant and Boehringer Ingelheim collaborate on integrated cloud platform to improve therapy development
April 12, 2023Medical Communications
US-based Cognizant and biopharmaceutical company Boehringer Ingelheim have announced a partnership to collaborate on ensuring the quality, and increasing the …
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
April 11, 2023Business Services
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 11, 2023 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), the essential life science …
Molecular Templates announces hold for phase 1 study
April 11, 2023Research and Development
Molecular Templates has announced that the FDA has placed a partial hold on its phase 1 study for MT-0169 based …
FDA authorises marketing of MISHA Knee System for patients with knee osteoarthritis
April 11, 2023Medical Communications
Medical device company, Moximed, has announced that the FDA granted marketing authorisation of its MISHA Knee System, an implantable shock …
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
April 11, 2023Business Services
LONDON and RALEIGH, N.C., April 11, 2023 – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage …
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
April 11, 2023Business Services
Leiden, The Netherlands, April 11, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the first commercial …
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
April 6, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening …
AstraZeneca’s Lynparza approved by NHS England
April 6, 2023Medical Communications
NHS England has approved the use of AstraZeneca’s Lynparza (olaparib) for the treatment of patients with breast cancer and prostate …
Synapse receives FDA approval for its NeuRx DPS to treat patients with stable SCI
April 6, 2023Research and Development
Synapse Biomedical has announced that it has gained premarket approval (PMA) from the FDA for its NeuRxDiaphragm Pacing System (NeuRx …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
